| 发明名称 | Endometrial polyp stem cell | ||
| 摘要 | An endometrial polyp stem cell is disclosed in the present invention. The endometrial polyp stem cell is isolated from an endometrial polyp tissue, expresses vimentin, CD13, CD29, CD44, and CD90, and has no expression of CD1q, CD3, CD34, and CD45. | ||
| 申请公布号 | US9574175(B2) | 申请公布日期 | 2017.02.21 |
| 申请号 | US201113225911 | 申请日期 | 2011.09.06 |
| 申请人 | Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 发明人 | Ding Dah-Ching |
| 分类号 | C12N5/074;C12N5/0775;C12N5/095;C12N5/079;C12N5/077;C12N5/071 | 主分类号 | C12N5/074 |
| 代理机构 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. | 代理人 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. ;Jensen Steven M.;Emmons Richard B. |
| 主权项 | 1. A formulation comprising: an endometrial polyp stem cell, which is isolated from an endometrial polyp tissue wherein the endometrial polyp stem cell expresses vimentin, CD13, CD29, CD44, and CD90, and has TERT expression statistically significantly lower than a human embryonic stem cell or a cancer cell, and an osteogenic medium comprising dexamethasone, β-glycerol phosphate, and ascorbate. | ||
| 地址 | Hualien TW | ||